GOSS
Price:
$0.91
Market Cap:
$205.87M
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system ...[Read more]
Industry
Biotechnology
IPO Date
2019-02-08
Stock Exchange
NASDAQ
Ticker
GOSS
According to Gossamer Bio, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.79. This represents a change of 611.59% compared to the average of -0.67 of the last 4 quarters.
The mean historical PE Ratio of Gossamer Bio, Inc. over the last ten years is -681.58. The current -4.79 PE Ratio has changed -29.72% with respect to the historical average. Over the past ten years (40 quarters), GOSS's PE Ratio was at its highest in in the June 2024 quarter at 1.09. The PE Ratio was at its lowest in in the March 2017 quarter at -2490.13.
Average
-681.58
Median
-4.07
Minimum
-5367.15
Maximum
-0.76
Discovering the peaks and valleys of Gossamer Bio, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 29.06%
Maximum Annual PE Ratio = -0.76
Minimum Annual Increase = -98.77%
Minimum Annual PE Ratio = -5367.15
Year | PE Ratio | Change |
---|---|---|
2023 | -0.77 | 1.38% |
2022 | -0.76 | -77.52% |
2021 | -3.40 | 29.06% |
2020 | -2.63 | -44.35% |
2019 | -4.73 | -35.82% |
2018 | -7.37 | -88.79% |
2017 | -65.79 | -98.77% |
The current PE Ratio of Gossamer Bio, Inc. (GOSS) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.65
5-year avg
-2.46
10-year avg
-681.58
Gossamer Bio, Inc.’s PE Ratio is less than Biomea Fusion, Inc. (-1.83), greater than Stoke Therapeutics, Inc. (-7.92), greater than Akero Therapeutics, Inc. (-8.95), less than Homology Medicines, Inc. (-0.01), less than Replimune Group, Inc. (-3.26), greater than Nuvectis Pharma, Inc. (-4.95), less than Lyra Therapeutics, Inc. (-0.18), less than Kronos Bio, Inc. (-0.58), less than Passage Bio, Inc. (-0.57), less than Black Diamond Therapeutics, Inc. (-3.70), less than TCR2 Therapeutics Inc. (-0.44), less than Harpoon Therapeutics, Inc. (-2.94), less than Alector, Inc. (-2.92), greater than Terns Pharmaceuticals, Inc. (-6.06), less than Amylyx Pharmaceuticals, Inc. (-0.97), less than Acumen Pharmaceuticals, Inc. (-2.06), less than Inozyme Pharma, Inc. (-3.48), less than X4 Pharmaceuticals, Inc. (7.41), less than Atreca, Inc. (-0.04), greater than 4D Molecular Therapeutics, Inc. (-7.58),
Company | PE Ratio | Market cap |
---|---|---|
-1.83 | $256.37M | |
-7.92 | $773.92M | |
-8.95 | $1.83B | |
-0.01 | $3.02M | |
-3.26 | $708.49M | |
-4.95 | $115.27M | |
-0.18 | $17.85M | |
-0.58 | $59.36M | |
-0.57 | $43.48M | |
-3.70 | $305.13M | |
-0.44 | $58.11M | |
-2.94 | $865.08M | |
-2.92 | $472.01M | |
-6.06 | $549.60M | |
-0.97 | $161.36M | |
-2.06 | $133.38M | |
-3.48 | $312.42M | |
7.41 | $109.78M | |
-0.04 | $3.57M | |
-7.58 | $783.18M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gossamer Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Gossamer Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Gossamer Bio, Inc.'s PE Ratio?
How is the PE Ratio calculated for Gossamer Bio, Inc. (GOSS)?
What is the highest PE Ratio for Gossamer Bio, Inc. (GOSS)?
What is the 3-year average PE Ratio for Gossamer Bio, Inc. (GOSS)?
What is the 5-year average PE Ratio for Gossamer Bio, Inc. (GOSS)?
How does the current PE Ratio for Gossamer Bio, Inc. (GOSS) compare to its historical average?